Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maher Albitar

Showing results (171-180 of 214) with videos related to

Pageof 22
Sort By:
Cancer|August 27, 2004
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodiesMaher Albitar, Kim-Anh Do, Marcella M Johnson, et al.
British Journal of Haematology|November 10, 2009
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)Gheath Alatrash, Maher Albitar, Susan O'Brien, et al.
British Journal of Haematology|February 13, 2003
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemiaWilliam G Wierda, Marcella M Johnson, Kim-Anh Do, et al.
Cancer|April 4, 2006
Thalidomide therapy for myelofibrosis with myeloid metaplasiaDeborah A Thomas, Francis J Giles, Maher Albitar, et al.
Cancer|December 12, 2003
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemiaSusan M O'Brien, Hagop M Kantarjian, Deborah A Thomas, et al.
BMC Medical Genetics|November 17, 2010
Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndromeWanlong Ma, Hagop Kantarjian, Ke Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaMichael J Keating, Susan O'Brien, Maher Albitar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2020
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic ModelInhye E Ahn, Xin Tian, David Ipe, et al.
Cancers|April 13, 2024
Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Graft-versus-Host Disease and Overall Survival after Allogeneic Stem Cell TransplantationScott D Rowley, Thomas S Gunning, Michael Pelliccia, et al.
Blood|May 6, 2003
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndromeHesham M Amin, Iman Jilani, Elihu H Estey, et al.
Pageof 22

Showing results (171-180 of 214) with videos related to

Sort By:
Pageof 22
Cancer|August 27, 2004
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodiesMaher Albitar, Kim-Anh Do, Marcella M Johnson, et al.
British Journal of Haematology|November 10, 2009
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)Gheath Alatrash, Maher Albitar, Susan O'Brien, et al.
British Journal of Haematology|February 13, 2003
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemiaWilliam G Wierda, Marcella M Johnson, Kim-Anh Do, et al.
Cancer|April 4, 2006
Thalidomide therapy for myelofibrosis with myeloid metaplasiaDeborah A Thomas, Francis J Giles, Maher Albitar, et al.
Cancer|December 12, 2003
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemiaSusan M O'Brien, Hagop M Kantarjian, Deborah A Thomas, et al.
BMC Medical Genetics|November 17, 2010
Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndromeWanlong Ma, Hagop Kantarjian, Ke Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaMichael J Keating, Susan O'Brien, Maher Albitar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2020
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic ModelInhye E Ahn, Xin Tian, David Ipe, et al.
Cancers|April 13, 2024
Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Graft-versus-Host Disease and Overall Survival after Allogeneic Stem Cell TransplantationScott D Rowley, Thomas S Gunning, Michael Pelliccia, et al.
Blood|May 6, 2003
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndromeHesham M Amin, Iman Jilani, Elihu H Estey, et al.
Pageof 22